Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Effectiveness of Concomitant Mitral Transcatheter Edge-to-Edge Repair and Left Atrial Appendage Closure.
Frazzetto M, Sanfilippo C, Costa G, Scandura S, Castania G, De Santis J, Sanfilippo M, Di Salvo ME, Uccello S, Rugiano G, Rizzo S, Barbera C, Tamburino C, Barbanti M, Grasso C. Frazzetto M, et al. Among authors: sanfilippo m, sanfilippo c. J Clin Med. 2023 Jul 18;12(14):4742. doi: 10.3390/jcm12144742. J Clin Med. 2023. PMID: 37510857 Free PMC article.
A focus on the percutaneous therapy of mitral and tricuspid regurgitation.
Frazzetto M, Sanfilippo C, Ferrarotto L, Tamburino C. Frazzetto M, et al. Among authors: sanfilippo c. Eur Heart J Suppl. 2023 Apr 21;25(Suppl B):B155-B160. doi: 10.1093/eurheartjsupp/suad095. eCollection 2023 Apr. Eur Heart J Suppl. 2023. PMID: 37091654 Free PMC article.
Safety and Efficacy of Percutaneous Left Atrial Appendage Closure Without Preprocedural Imaging.
Sanfilippo C, Frazzetto M, Costa G, Contrafatto C, Giacalone C, Tricomi G, Barbera C, Rizzo S, De Santis J, Sanfilippo M, Castania G, Di Salvo ME, Scandura S, Tamburino C, Barbanti M, Grasso C. Sanfilippo C, et al. Among authors: sanfilippo m. Circ Cardiovasc Interv. 2024 Jul;17(7):e014183. doi: 10.1161/CIRCINTERVENTIONS.124.014183. Epub 2024 Jun 17. Circ Cardiovasc Interv. 2024. PMID: 38881462 No abstract available.
Abdominal wall complications after kidney transplantation: A clinical review.
Gioco R, Sanfilippo C, Veroux P, Corona D, Privitera F, Brolese A, Ciarleglio F, Volpicelli A, Veroux M. Gioco R, et al. Among authors: sanfilippo c. Clin Transplant. 2021 Dec;35(12):e14506. doi: 10.1111/ctr.14506. Epub 2021 Oct 28. Clin Transplant. 2021. PMID: 34634148 Free PMC article. Review.
Quality of Life and Related Factors in Patients Diagnosed with Mucopolysaccharidosis and Their Caregivers.
Yekedüz MK, Cilesiz K, Kara İS, İnci A, Kose E, Tümer L, Eminoğlu FT. Yekedüz MK, et al. Klin Padiatr. 2024 Dec 10. doi: 10.1055/a-2451-6562. Online ahead of print. Klin Padiatr. 2024. PMID: 39657772 English.
OBJECTIVES: Quality of life (QoL) is directly associated with physical-psychological well-being, family and environmental factors in patients with Mucopolysaccharidosis (MPS). The present study aims to investigate the factors affecting QoL in both MPS patients and their ca …
OBJECTIVES: Quality of life (QoL) is directly associated with physical-psychological well-being, family and environmental factors in patient …
Heparan sulfate in cerebrospinal fluid as a biomarker to assess disease severity and for treatment monitoring in patients with Mucopolysaccharidosis Type II: a position statement.
Giugliani R, de Siqueira ACM, Santos ES, Leão EKEA, Carvalho GDS, Santos MLSF, Raskin S, Martins AM. Giugliani R, et al. Orphanet J Rare Dis. 2024 Nov 26;19(1):436. doi: 10.1186/s13023-024-03463-9. Orphanet J Rare Dis. 2024. PMID: 39593190 Free PMC article.
Patients with mucopolysaccharidosis type II (MPS II) can present with a severe neuronopathic phenotype or an attenuated non-neuronopathic phenotype. ...The recommended timing of HS evaluations in CSF of patients with the severe phenotype is: (i) before treatment; (ii) six …
Patients with mucopolysaccharidosis type II (MPS II) can present with a severe neuronopathic phenotype or an attenuated non-neuronopa …
Development of a novel tool for individual treatment trials in mucopolysaccharidosis.
Wiesinger AM, Bigger B, Giugliani R, Lampe C, Scarpa M, Moser T, Kampmann C, Zimmermann G, Lagler FB. Wiesinger AM, et al. J Inherit Metab Dis. 2024 Nov 21. doi: 10.1002/jimd.12816. Online ahead of print. J Inherit Metab Dis. 2024. PMID: 39572375
Mucopolysaccharidosis (MPS) encompasses a group of genetic lysosomal storage disorders, linked to reduced life expectancy and a significant lack of effective treatment options. ...The iterative methodology of our novel decision analysis framework (DAF) involves three key s …
Mucopolysaccharidosis (MPS) encompasses a group of genetic lysosomal storage disorders, linked to reduced life expectancy and a signi …
Extracellular vesicles from microglial cells activated by abnormal heparan sulfate oligosaccharides from Sanfilippo patients impair neuronal dendritic arborization.
Dias C, Ballout N, Morla G, Alileche K, Santiago C, Guerrera IC, Chaubet A, Ausseil J, Trudel S. Dias C, et al. Mol Med. 2024 Nov 4;30(1):197. doi: 10.1186/s10020-024-00953-1. Mol Med. 2024. PMID: 39497064 Free PMC article.
BACKGROUND: In mucopolysaccharidosis type III (MPS III, also known as Sanfilippo syndrome), a pediatric neurodegenerative disorder, accumulation of abnormal glycosaminoglycans (GAGs) induces severe neuroinflammation by triggering the microglial pro-inflammato …
BACKGROUND: In mucopolysaccharidosis type III (MPS III, also known as Sanfilippo syndrome), a pediatric neurodegenerati …
1,263 results